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Matrix metalloproteinases (MMPs) are important enzymes for extracellular matrix 
degradation. Cleavage of collagen by MMP-8 is an important regulator of tissue remodeling in 
wound healing and repair, but it also contributes to the exacerbation of several inflammatory 
diseases and can serve a protective role in early stages of cancer. In addition through its 
enzymatic activity, MMP-8 directly effects disease progression through up-regulation or down-
regulation of key inflammatory mediators and proteins involved in tissue repair, neutrophil 
migration, and inflammation. As such, MMP-8 has been a therapeutic target for inhibition with 
the aim to improve patient care and outcomes for several inflammatory diseases, such as 
periodontitis, asthma, and rheumatoid arthritis. Several MMP-8 inhibitors have been 
investigated, but often, the mechanisms of inhibition are not fully understood. To better 
understand MMP-8 inhibition, high-resolution solution nuclear magnetic resonance (NMR) 
spectroscopy has been used to study protein structure under different conditions and to track 
perturbations from inhibitor interactions. Knowing the mechanism of inhibitor interaction would 
allow for the development of more selective and potent MMP-8 inhibitors. The primary 
objectives of this thesis are to give an overview of the mechanistic action of MMP-8 in the 
immune response, to understand the structure and behavior of MMP-8 in various conditions 
using NMR spectroscopy, and to explore interaction of this enzyme with the unique metal 
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BIOLOGICAL MECHANISMS OF ACTION OF MMP-8 IN INFLAMMATORY 
DISEASE STATES AND THE CHEMICAL MECHANISMS OF ITS INHIBITORS FOR 
CONTROLLING DISEASE PROCESSES 
 
1.1 INTRODUCTION 
 Matrix metalloproteinase (MMP)-8 is a member of the MMP family of enzymes that 
catalyze hydrolysis of proteinaceous substrates. The large MMP family consists of 25 vertebrate 
MMPs, 23 of which are present in humans [1, 2]. MMPs are Zn
2+
-dependent proteinases that can 
be separated into collagenases, gelatinases, stromelysins, matrilysins, and membrane-type 
MMPs. MMP-8 falls into the collagenase group and is also referred to as collagenase-2 or 
neutrophil collagenase [1]. As other names imply, MMP-8 is involved in the cleavage of 
collagen and was thought originally to be expressed solely by neutrophils. However, further 
studies have identified MMP-8 expression in several other cell types, including odontoblasts, 
epithelial cells, and macrophages [3, 4]. With expression by many cell types, MMP-8 plays a 
role in several inflammatory diseases, such as periodontitis, sepsis, asthma and rheumatoid 
arthritis, and cancers [5, 6], and as such is a sought after target of drug design.  
1.2 BIOLOGICAL ROLE OF MMP-8 
 MMP-8 plays a role in the breakdown of extracellular matrix for tissue remodeling and 
repairs by cleaving collagen fibers. MMP-8 cleaves type I collagen fibers more efficiently than 
type II and III collagen fibers and cleaves the fibers at a specific site three-fourths from the       
N-terminus, resulting in a three-fourth length N-terminal peptide and a one-fourth length           
C-terminal peptide [5, 7-10]. Overexpression of MMP-8 can lead to increased breakdown of 
collagen and exacerbation of inflammatory response. MMP-8 is also involved in cancer 
progression and has long been thought to promote the growth of cancerous tumors, but more 





limit tumor formation and spreading [5, 6]. In studying the importance of MMP-8 in diseases, 
several clinical studies have focused on the elevated expression of MMP-8 in the presence of 
periodontal diseases. MMP-8 expression levels in gingival crevicular fluid (GCF), saliva, and 
serum have been positively correlated with the presence of periodontitis, periodontal disease 
severity, and several periodontal clinical parameters [11-14]. When patients undergo nonsurgical 
periodontal treatment, MMP-8 levels decrease toward a non-disease level concomitant with a 
decrease in the severity of the periodontitis [14-18]. Because MMP-8 levels are closely and 
positively correlated with the presence of periodontitis, several enzyme-linked immunosorbent 
assay (ELISA) and immunofluorometric assay (IFMA) chair-side tests have been developed for 
easier, cheaper, and noninvasive diagnosis by clinicians using GCF [19-22].  
 Altered MMP-8 levels have been observed in other inflammatory diseases, including 
rheumatoid arthritis [23], asthma [24], chronic obstructive pulmonary disease (COPD) [25, 26], 
and sepsis [27, 28]. Often, increased MMP-8 levels are associated with worsened disease 
severity. However, in some cancers, MMP-8 serves a protective, anti-tumor role. For example, 
MMP-8 deficient mice (heterozygous and null) had a faster onset of mammary gland tumors and 
metastasis in the lungs compared to wild-type mice [29]. Previous review articles have further 
explained the presence of MMP-8 in inflammatory diseases and cancer and provided more 
information about the clinical relevance of MMP-8 [5, 6, 30-34]. Although much of the literature 
involving MMP-8 is based on clinical studies, the purpose of this chapter is to summarize the 
mechanistic action of MMP-8 that underlies its role in these diseases.  
1.3 MECHANISTIC/FUNCTIONAL ROLE IN INFLAMMATION 
 Because the involvement of MMP-8 in inflammatory diseases and cancers is complex, 





mechanistic roles of MMP-8 in these disease processes. MMP-8 has a complex role in disease 
progression through involvement in the regulation of inflammatory mediators, macrophage and 
immune cell migration, and tissue repair and regeneration. During immune response, several 
inflammatory cytokines are released, mainly from helper T cells (Th) and macrophages, and 
affect cell-cell interactions and communications [35]. Pro-inflammatory cytokines, such as 
interleukin (IL)-6, IL-1β, and tumor necrosis factor (TNF)-α, upregulate inflammatory reactions, 
and anti-inflammatory cytokines, such as IL-4 and IL-10, help to control the pro-inflammatory 
response. Upregulation of MMP-8 in disease states disrupts the normal balance of cytokines and 
can lead to worsening of the disease through increased inflammation (Figure 1.1).  
1.3.1 Regulation of Inflammatory Mediators 
  MMP-8 regulates multiple inflammatory mediators in several inflammatory diseases and 
cancers. In cancer cells with demonstrated increased expression of MMP-8, IL-6 and IL-8 had 
increased expression compared to control and MMP-8 mutant cells, suggesting that MMP-8 
participates in the regulation of these pro-inflammatory mediators during tumor metastasis and 
tissue repair [36]. Furthermore, studies of MMP-8 null mice resulted in decreased neutrophil 
infiltration in the lung and decreased circulating levels of IL-6 and IL-1β pro-inflammatory 
cytokines in sepsis mice models [27]. MMP-8 has been found to activate lipopolysaccharide-
induced CXC chemokine (LIX) chemotactic activity by cleaving the precursor LIX, and 
activated LIX modulates and increases neutrophil infiltration [37]. Some cytokines, such as IL-
1β, are produced as precursor proteins, and other MMPs have been found to activate cytokines 
by proteolytic removal of the N-terminal part [38]. MMP-8 likely functions in a similar manner 







cleavage, in a manner similar to collagen cleavage, and inactivation of mature cytokines. MMP-8 
regulation of pro-inflammatory mediators is important for disease severity and progression. 
MMP-8 also contributed to increased inflammation in ventilator-induced lung injury. 
Genetic and pharmacological elimination of MMP-8 results in reduced inflammation and 
increased levels of anti-inflammatory cytokines (IL-4, IL-10) in lung tissue and fluid in mice 
after high-pressure ventilation compared to wild-type mice [39]. MMP-8 may play a role in 
neutrophil apoptosis by controlling neutrophilic and eosinophilic recruitment into allergen-
induced lung inflammation [40]. Additionally, IL-4 activates rearrangement of neutrophil 
cytoskeleton, potentially activates neutrophilic protein synthesis, and delays neutrophil apoptosis 
Figure 1.1 Regulatory role of MMP-8 in inflammatory response. MMP-8 upregulates and downregulates 
several cytokines and influences several processes, including macrophage differentiation, neutrophil infiltration, 






[41]. Upregulation of IL-4 in the absence of MMP-8 suggests that IL-4 also modulates neutrophil 
recruitment. It is possible that MMP-8 may not directly control neutrophil apoptosis and 
inflammation and may be controlling indirectly these processes by regulating IL-4 cytokine 
levels. As for IL-10, MMP-8 regulates IL-10 by cleaving and thus inactivating the cytokine [42]. 
In the absence of MMP-8 enzymatic action, IL-10 levels increase, and inflammation decreases.  
 In neuroinflammatory disorders, such as sepsis, MMP-8 is involved in inflammatory 
regulation of TNF-α, a pro-inflammatory cytokine [43]. It is also possible that MMP-8 activates 
the pro-inflammatory transcription factor-nuclear factor-kappaB (NF-κB) and causes increased 
inflammation [27]. The role of MMP-8 as a regulator of several inflammatory mediators makes 
MMP-8 a key target for treatment of many inflammatory diseases. Targeting MMP-8 with 
inhibitors will shut down MMP-8 enzymatic function and result in decreased inflammation and 
improved disease prognosis. Because this enzyme can exert different effects on unique disease 
states at individual stages of disease progression, understanding the complex behavior and 
involvement of MMP-8 is critical for achieving the desired therapeutic effect. 
1.3.2 Immune Cell and Macrophage Migration 
 MMP-8 indirectly causes reduced migration of macrophages and CD4+ lymphocytes into 
lungs after lung injury. Upregulation of MMP-8 causes decreased macrophage inflammatory 
protein (MIP)-1α and interferon-γ inducible protein (IP)-10 lung levels, which reduced migration 
of macrophages and CD4+ lymphocytes [44]. MMP-8 restrains lung inflammation by cleaving 
and inactivating MIP-1α [45]. Reduced levels of IP-10 can be explained by fewer macrophages 
activated by MIP-1α because a significant source of IP-10 is from activated macrophages [46]. 





potent chemoattractant for macrophages [47] and lymphocytes [48], which are increased by     
IP-10 in lung inflammation models [49].  
Contradictory results regarding MMP-8 and CD8+ T cells were reported in a separate 
study involving children with gingivitis and Down syndrome. In this study, a significant positive 
correlation between MMP-8 and CD8+ T cells was observed [50]. Individuals with Down 
syndrome have altered immune responses due to reduced chemotactic ability, interruptions in   
T- and B-cell subpopulations, and impaired polymorphonuclear leukocytes phagocytosis [51-53]. 
In children with Down syndrome and altered immune response, it is possible that MMP-8 
facilitates migration of immune cells into periodontal tissue, which does not occur in controls, 
and this may lead to more extensive periodontal tissue degradation [50].  
 MMP-8 also controls transforming growth factor (TGF)-β bioactivity, which indicates a 
role of MMP-8 involvement in macrophage differentiation and polarization through promoting 
M2-macrophage differentiation [54]. MMP-8 deficient macrophage culture media had a lower 
level of TGF-β compared to wild-type macrophage culture media. It has been demonstrated that 
TGF-β levels in lung, especially macrophages, is decreased by IL-10 [55]. Because MMP-8 
cleaves IL-10, it is possible that the enzyme indirectly prevents inhibition of TGF-β by 
decreasing IL-10 levels. 
1.3.3 Tissue Repair and Regeneration 
 MMP-8 is a key component of dentin collagen degradation. In an in vitro study, dentin 
collagen fibrils changed and disappeared several hours after treatment with MMP-8. However, 
the degradation was prevented when the collagen fibrils were treated with chlorhexidine or 
captopril in the solution to inhibit MMP-8 [56]. MMP-8 was detected in the mineralized and 





that MMP-8 is the major collagenase in dentin. The lesser amounts of MMP-8 compared to 
dental gelatinases bound to mineralized dentin suggest that MMP-8 may be more involved in 
dentin matrix organization than mineralization [57].  
 In a study with MMP-8 null mice, it was found that MMP-8 is involved in tongue wound 
healing by regulating TGF-β1 (Figure 1.2). MMP-8 null mice and MMP-8 null fibroblasts had 
higher expression levels of TGF-β1 than wild-type mice and fibroblasts [58]. MMP-8 was found 
to inhibit TGF-β1 activity through the cleavage of decorin in a breast cancer cell study [59]. In 
MMP-8 null mice, tongue wounds healed faster initially (6-24 hours) compared to wild-type 
mice, which suggests that MMP-8 delays 
the wound healing process [58]. The 
opposite effect was seen for skin wounds 
which healed faster in wild-type mice than 
MMP-8 null mice [60]. In the latter study, 
MMP-8 null mice also exhibited lower 
levels of active TGF-β1 and increased 
levels of pSmad2 and pSmad3, TGF-β1 
intracellular effectors. TGF-β1 signaling 
regulates wound healing processes [61, 
62], and these results suggest that TGF-β1 
and members of the Smad family 
contribute to the increased neutrophil 
infiltration observed in MMP-8 null     
mice [60]. MMP-8 null mice also had 
Figure 1.2 Role of MMP-8 in tissue repair. MMP-8 has 
been found to both upregulate and down regulate TGF-β1 
and downregulates TGF-β1 intracellular effectors, pSmad2 
and pSmad3, during tissue repair and regeneration. MMP-8 
is upregulated under high stress conditions while TIMP-1 
regulates matrix remodeling by inhibiting MMP-8. The 
balance of MMP-8 upregulation and inhibition is important 





decreased neutrophil apoptosis, which possibly leads to continued inflammation in skin    
wounds [60]. TGF-β1 activation by MMPs has also been demonstrated in several other studies 
[63-65]. MMP-8 regulation of TGF-β1 plays an important role in healing and inflammation.   
Stress and strain cause differences in expression of MMP-8 and affect inflammation and 
healing. In addition to delayed healing of chronic wounds [66, 67], overexpression of MMP-8 
may be linked to stress-impaired healing of acute wounds with persisting high levels of 
neutrophils at the wound site. When wounds of stressed and non-stressed mice were compared, 
differences in orientation of collagen fibrils were observed. These differences potentially 
associate MMP-8 overexpression with poorer collagen formation in wound healing, which 
results in scarring [68]. The disorganization and poor architecture of collagen fibrils in stressed 
mice caused greater scarring at the wound sites. A study using human periodontal ligament 
fibroblasts (HPdLF) found that high static tensile strain (STS) of 10% was needed to cause 
significantly increased production of MMP-8, an indicator of periodontal inflammation and 
extracellular degradation. However, tissue inhibitor of matrix metalloproteainase (TIMP)-1 
levels were also elevated at 10% STS, so high STS most likely causes extracellular matrix 
alteration, rather than degradation, since TIMP-1 binds to and inhibits MMP-8 (Figure 1.2) [69]. 
Through inhibition, TIMP-1 controls MMP-8 activity and prevents complete degradation of the 
extracellular matrix.  
MMP-8 is also associated with the immune response related to cellular death through 
tissue necrosis, a negative, pro-inflammatory outcome of wound healing. During necrosis, the 
plasma membrane rapidly becomes permeable and cellular contents are released to the 
intracellular space, often inducing an inflammatory response [70]. The presence of MMP-8 at the 





levels of MMP-8 at a site of necrosis also are important for collagen breakdown in tissue 
remodeling during necrosis. In tissue remodeling, MMP-8 expression is present in nerve fibers, 
including nerve fiber growth cones and is upregulated by the nerve growth factor (NGF) in 
cultured neurons. MMP-8 plays an important role in nerve fiber penetration into collagen I 
fibers. When MMP-8 was inhibited or neutralized by an antibody, nerve fibers did not penetrate 
and extend into the basement membrane, and nerve fiber growth was blocked by collagen fibers. 
It is possible that nerve fibers release MMP-8, which cleaves the nearby collagen fibers, to 
stimulate nerve growth into the collagen matrix [72]. 
1.4 INHIBITION 
 Overexpression of MMP-8 in inflammatory diseases and some cancers causes deleterious 
effects, as seen with the roles of MMP-8 described above. MMP-8 is a useful biomarker and 
serves as a good drug target in the treatment of these diseases. The presence of MMP-8 during 
disease progression leads to increased inflammation and worsening of disease state, and 
inhibiting the enzyme would allow for faster, improved recovery. MMP-8 levels are consistently 
elevated in inflammatory diseases, whereas the expression levels of other biomarkers have been 
found to vary. MMP-8 also regulates several inflammation and tissue repair pathways that affect 
disease outcome, making MMP-8 a good drug target. MMP-8 and similar enzymes serve 
important regulatory functions throughout the body, so complete inhibition of MMP-8 would 
prevent necessary functions and lead to even greater health problems. Inhibition of MMP-8 can 
be accomplished in a number of ways, but achieving potent, selective inhibition at the site of 
aberrant activity has proven very challenging because of the ubiquitous expression and need for 





Various approaches have been investigated for the development of MMP-8 inhibitors. 
Both small and large molecules have proven to be effective at blocking MMP-8 activity. In the 
development of inhibitors, the enzyme’s catalytic site is the main target to block the active site 
and prevent cleavage of collagen fibers. Other inhibitors bind to sites nearby the MMP-8 
catalytic site and sterically block collagen from entering the active site. Inhibition of MMP-8 
also obstructs the enzyme’s regulatory role in inflammatory response and tissue repair.  
The structure of MMP-8 is important for understanding the mechanisms of inhibitor 
interaction. A crystal structure revealed a smaller α-helical C-terminal subdomain separated from 
a larger N-terminal domain, composed of two α-helices, a five-stranded β-sheet, and bridging 
loops, by an active-site cleft [75]. The catalytic domain holds a catalytic Zn
2+
 ion at the bottom 
of the cleft and another non-exchangeable Zn
2+
 ion and two Ca
2+
 ions on top of the β-sheet 
(Figure 1.3). When collagen fibers, each comprised of two α1-chains and one α2-chain, undergo 
cleavage, the α2-chain unwinds from the rest of the fibril, orients into the active-site cleft, and 
interacts with the catalytic Zn
2+
 ion and nearby MMP-8 residues (Figure 1.4) [76]. In addition to 
the active site, MMP-8 has additional active sites known as subsites (S), which can interact with 
substrates [77, 78]. Subsites Sn and Sn’ are on the left and the right of the catalytic Zn
2+
 ion, 
respectively, and some of the subsites are labeled in Figure 1.5A. The sites on the substrates or 
inhibitors that interact with the subsites are termed Pn and Pn’, respectively. The S1’ pocket is 
the substrate binding site next to the catalytic Zn
2+
 ion and is a main contributor to determination 
of inhibitor affinity [79]. Developing inhibitors that interact with MMP-8 in a similar manner as 





Effective inhibitors would interact with the catalytic Zn
2+
 ion and hydrogen bond to residues in 
the active site to prevent MMP-8 interaction with collagen.  
Inhibition of MMP-8 has been demonstrated with the use of silver diamine fluoride 
(SDF) [80]. Increasing percentages of SDF showed greater inhibition. The investigators also 
tested NaF and AgNO3 at equivalent amounts of fluoride and silver, respectively. The percentage 
of MMP-8 inhibition was significantly higher by the SDF solutions than the NaF and AgNO3 
solutions, but the mechanism of inhibition is unknown. In clinical studies, the use of SDF has 
shown potential to prevent progression of dental caries [81-83]. In spite of the potential anti-
caries benefits, SDF has not realized widespread adoption because the treated teeth are stained 
black. Inhibition of MMP-8 with SDF prevents enzymatic degradation of dentin.  
Figure 1.3 Stereo plot ribbon model of MMP-8 (79-242) from crystal structure. A five-stranded β-sheet and 
two α-helices make up the N-terminal domain of MMP-8, and the C-terminal domain consists of one α-helix. 
The catalytic Zn
2+





 ions are positioned above the β-sheet. Bound BB-1909 inhibitor is shown as a green stick model 
interacting with the catalytic Zn
2+






Sepsis model rats had elevated MMP-8 
expression levels in the myocardium compared to 
control rats. Sepsis model rats that underwent 
treatment with dexamethasone (DEX) had statistically 
identical MMP-8 levels compared with untreated 
sepsis rats [84]. DEX treatment has been shown to 
reduce expression levels of other MMPs [85, 86] but 
did not have the same effect on MMP-8. However, 
significantly lower MMP-8 expression was observed 
in sepsis rats after treatment with the MMP-8 inhibitor 
M8I ((3R)-(+)-[2-(4-Methoxybenzenesulfonyl)-
1,2,3,4-tetrahydroisoquinoline-3-hydroxamate]). M8I may improve the outcome of sepsis 
induced myocardial injury [84]. Inhibition of MMP-8 in sepsis patients reduces the levels of pro-
inflammatory cytokines IL-1β and TNF-α which may lessen the degree of myocardial injury.  
In the case of tuberculosis (TB), NF-κB inhibitors p65 subunit helenalin, caffeic acid 
phenethyl ester (CAPE), and SN50 inhibited MMP-8 production while maintaining neutrophil 
activity. These NF-κB inhibitors prevented neutrophil secretion of MMP-8 and may prevent 
tissue destruction by MMP-8 in patients with TB. Collagen destruction was also decreased by a 
MMP-8 neutralizing antibody. Neutrophil collagenase activity was reduced to normal in TB 
patients treated with doxycycline [87]. Inhibition of MMP-8 by doxycycline is in line with 
previous studies [88, 89]. Doxycycline inhibition is not specific for MMP-8 and interacts with 
domains of other MMPs. A study with truncated enzymes suggests that doxycycline disrupts the 
conformation of the catalytic domain of MMP-8 [90].  
Figure 1.4 MMP-8 cleavage of collagen. 
The collagen α2 chain, in the MMP-8 active 
site, interacts with the catalytic Zn
2+
 ion 
(purple sphere) and H-bonded to MMP-8 
residues (red lines). Modified and 
reproduced with permission from J. Mol. 





MMP-8 activity was also inhibited in human neutrophils when incubated with 
chlorohexidine (CHX) [91]. Addition of calcium chloride prevented MMP-2 and MMP-9 
inhibition by CHX, which suggests that CHX may inhibit the MMPs through a chelating 
mechanism. Inhibition through cation chelation was also suggested in a study of MMP-8 
inhibition by dichloromethylene bisphosphonate (clodronate) [92]. In vivo, chelation of the 
catalytic Zn
2+




 ions in MMP-8 is not a selective approach for 
inhibition. Many enzymes and other proteins depend on binding to metal ions for their function 
and/or structure and are disrupted by treatment with chelators [93]. The unintended removal of 
metal ions from other enzymes by chelators leads to more diverse side effects, so caution must 
be taken when inhibiting MMP-8 through chelation. 
Inhibitor interaction with the MMP-8 catalytic Zn
2+
 ion has previously been studied [94]. 
The crystal structure of MMP-8 with BB-1909, a derivative of the broad-spectrum MMP 
inhibitor batimastat, display the catalytic Zn
2+
 liganded by the three histidine nitrogen atoms in 
MMP-8 and by the hydroxyl oxygen and carbonyl oxygen of the hydroxamate group of BB-1909 
in a bidentate manner (Figure 1.3). The side chain of Glu198 also coordinates with the 
hydroxamate hydroxyl, and the carbonyl of Ala161 and Glu198 coordinate with the hydroxamate 
nitrogen. Further, the orientation of the isobutyl group extends into the S1’ pocket of MMP-8. 
With similar molecular structure, BB-1909 and batimastat have almost equivalent interaction 
with MMP-8. The barbiturate ring of a barbiturate acid derivative (RO200-1770) interacts with 
MMP-8 in similar structural orientation as batimastat (Figure 1.5) [95]. Both the barbiturate ring 
of RO200-1770 and batimastat orient into the S1’ and S2’ pockets of MMP-8 while the N3 and 
O2 of the barbiturate ring and N and O of batimastat coordinate the Zn
2+





MMP-8 inhibition is also possible through inhibitor interaction outside of the active site, 
such as with antibodies and derivatives of these 
large molecules. A nanobody (Nb), which is 
derived from a Camelidae heavy-chain-only 
antibody, showed micromolar inhibition of 
mouse (mMMP-8) and human MMP-8 but very 
limited binding to other MMPs and 
metalloproteinases [96]. The Nbs were 
produced by immunization of Alpacas with the 
catalytic domain of mMMP-8, and they did not 
interact with several other MMPs. 
Macromolecular inhibitors are a growing class 
of therapeutics because of their exceptional 
selectivity, specificity, high affinity, longer 
circulation time, and minimal toxicity. They are    
a very good option for extracellular targets like 
Figure 1.5 MMP-8 substrate recognition site.   
(A) Representation of the interaction between 
MMP-8 and its substrates. The subsites, Sn and Sn’, 
and the interaction sites on the substrate, Pn and Pn’, 
are labeled. (B) Interaction of RO200-1770, a 
barbiturate acid derivative, with the MMP-8 active 
site. (C) Representation of batimastat interaction 
with the MMP-8 active site. Reproduced with 
permission from J. Biol. Chem. 276, 17405–17412 
© 2001 The American Society for Biochemistry and 





MMPs. Nb are smaller than antibodies and are retained in circulation for a shorter length of time. 
This molecule demonstrates selective inhibition of MMP-8 by a Nb, but the affinity and 
circulating half-life need to be improved to generate a clinically relevant lead candidate. Because 
larger molecules are retained in circulation longer, conjugation to increase the size of small 
proteins has been used to extend their time in the bloodstream [97-101]. When the Nb was 
conjugated with an anti-albumin Nb, a significantly longer half-life was achieved (28 hrs 
compared to 2 hrs without the anti-albumin Nb) and the conjugate maintained equivalent MMP-8 
binding and inhibitory abilities [96]. The specific interaction between this Nb and MMP-8 has 
not been determined experimentally, but computer modeling suggests that the Nb most likely 
binds to one of three possible locations, one at the active site and two outside the active site but 
still on the catalytic domain (Figure 1.6). The active site and another location might involve 
lysine residue recognition. Further testing revealed that the Nb most likely binds to one of the 
Figure 1.6 Nanobody (Nb) inhibitor interactions with MMP-8. (A) MMP-8 catalytic domain in gray has 
lysine residues on the surface, shown in cyan. The three locations indicate predicted Nb inhibitor binding places, 
shown by the Nb conformations in cyan (1), yellow (2), and green (3). The interaction with Nb in (2) occurs at 
the MMP-8 active site. (B) Stick conformation of lysine-lysine interaction between MMP-8 (gray) and Nb 
(green) is shown. Reproduced with permission from Mol. Ther. 24, 890-902 © 2016 The American Society for 






locations outside the active site and causes inhibition through steric hindrance or conformational 
changes of MMP-8. This initial success suggests that with modification to improve binding 
affinity this approach may be useful in the clinic.  
In addition to direct inhibitor interaction with MMP-8, other approaches have been 
investigated to inhibit the effects of MMP-8 action on its matrix substrates, including dentin. 
Dentin is composed of a collagenous matrix that largely is mineralized with hydroxylapatite but 
also contains substantial amounts of water and organic material [102]. The organic material is 
made up of 90% collagen, almost all type I, and 10% non-collagenous proteins and 
proteoglycans. Mineralization of dentin, through crystallization of calcium phosphate, hardens 
the tooth tissue, which is important for physiological function [102]. MMP-8 enzymatic action 
results in the cleavage of collagen fibers and ultimately the breakdown of dentin, which supports 
caries formation [103, 104]. Treatment of dentin with collagen crosslinkers, such as grape seed 
extracts, sumac extracts, and riboflavin, resulted in decreased levels of extractable dentinal 
MMP-8 compared to controls, as determined by zymography and enzyme activity assays [105]. 
Treatment with these compounds most likely covalently crosslinks collagen fibers, decreasing 
the size exclusion cut-off of the collagen matrix and preventing MMP-8 from being released. 
The crosslinking of collagen makes it more difficult to unwind the fibers, which slows cleavage 
of the collagen chains. Crosslinker treatment also results in covalent attachment of the enzyme to 
the matrix and inactivation of MMP-8. Although this approach is less likely to be used in 
therapeutic applications, it may have relevance to implanted biological restorations to inhibit the 
destructive action of MMP-8 in situ and increase longevity of the restoration. 
Although the inhibitors discussed above decrease expression of or inhibit MMP-8 by 





delineated for several MMP-8 inhibitors. Determination of the exact mechanism of a 
compounds’ inhibition is critical for achieving the desired effect for enzymes with broad 
expression in the body. Recent studies have suggested a possible mechanism of MMP-8 
inhibition by the tether-MAP peptide [106-108]. The metal abstraction peptide (MAP) is 
composed of the amino acid sequence NCC, and under neutral to basic pH it scavenges metal 
ions from other molecules [109]. Initial studies demonstrated that when chemically conjugated to 
2-aminoethyl methacrylate hydrochloride (AEMA) containing dental polymers, tether-MAP 
binds MMP-8 and inhibits enzymatic action. Based on understanding of the MAP peptide 
chemistry, it was hypothesized that inhibition is accomplished via the Zn
2+
 ion in MMP-8’s 
catalytic active site [106]. Additional investigation using self-assembled monolayers (SAMs) 
further support that the MAP Tag directly interacts with and confirms that it inhibits MMP-8 
through the Zn
2+
 ion in the active site [107].  
Follow up studies, similar to the surface studies on the dental polymers and SAMs, are 
needed to gain a better understanding of the intermolecular interaction between MMP-8 and 
MAP and to elucidate the specific mechanism of inhibition. This approach is advantageous 
because MAP has exceptionally high affinity and reduced toxicity compared to other small 
molecule inhibitors of MMP-8 and acts as a very slowly reversible inhibitor to mitigate the 
destructive activity of this enzyme in situ. Tether-MAP provided proof of concept, demonstrating 
the viability of using this peptide module to inhibit MMP-8, but this construct was not optimized 
to achieve selectivity solely for MMP-8. Because it is a peptide, the sequence around the metal-
binding module may be modified using standard screening techniques and/or rational design 
approaches to generate a molecule that more specifically interacts with MMP-8 to accomplish 






Although MMP-8 is used as a biomarker for several diseases, it also contributes to 
disease severity and outcome. This insight into the mechanistic role of MMP-8 in inflammatory 
diseases and cancer has linked together events of MMP-8 regulation of inflammatory mediators 
and proteins involved in tissue repair, neutrophil migration, and inflammation. To improve 
patient outcomes of relevant disease states, several approaches are available for inhibition of 
MMP-8. Further studies are needed to investigate the mechanism of inhibitor interaction with 
MMP-8 to continue to develop more specific inhibitors, but understanding the multiple 
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MMP-8 CONDITION OPTIMIZATION FOR HIGH-RESOLUTION SOLUTION NMR 
ANALYSIS OF ENZYME STABILITY AND INHIBITOR INTERACTIONS 
 
2.1 INTRODUCTION 
 Matrix metalloproteinase (MMP)-8 plays an important role in the development and 
progression of several inflammatory diseases, such as periodontitis, asthma, and rheumatoid 
arthritis. Through regulation of inflammatory mediators, MMP-8 causes increased inflammation 
and worsening of disease state, and the mechanisms by which it participates in disease 
progression are discussed in detail in Chapter 1. Because of its destructive role in activating key 
pathways, it is strongly believed that inhibition of MMP-8 would reduce inflammation in patients 
with these conditions and lead to better disease management and prognosis. Several MMP-8 
inhibitors have been tested in cell culture and rat models, and some of these compounds also 
have been tested in the clinic to control inflammatory diseases, such as periodontitis. However, 
the mechanism of inhibition is not always known.  
Understanding the mechanism by which inhibition is accomplished is important for drug 
discovery and development in order to obtain the most desirable therapeutic outcome, especially 
for drugs that affect targets involved in multiple pathways and functions in the body. Inhibitors 
can interact with an enzyme and prevent enzymatic function for different lengths of time, 
influenced by inhibitor size and binding efficiency, which alters the amount of inhibitor needed 
to achieve the desired level of inhibition [1]. Knowing more information about the structure of 
MMP-8, where an inhibitor can bind to the enzyme, and how the inhibitor impedes enzymatic 
action will contribute to the understanding of the methods of inhibitor interaction with this 






 As a member of the MMP family, MMP-8 is difficult to express because its proteolytic 
activity leads to autoproteolysis [2]. Preparing the protein as a thioredoxin (Trx)-MMP-8 fusion 
construct improves the stability of MMP-8, which allows for high-yield protein production and 
enables analysis [3]. Trx helps maintain the folded protein structure by a yet known mechanism 
and improves the stability of MMP-8 by folding with and preventing cleavage of MMP-8 [4]. 
The longer lifetime of MMP-8 is required to conduct more detailed structural and biophysical 
analyses such as three-dimensional (3D) nuclear magnetic resonance (NMR) experiments.  
 High-resolution solution NMR is an important tool in the pharmaceutical industry to 
understand protein-drug interactions [5]. Tracking perturbations in the physical properties of the 
protein provides information about protein structure, mechanism of binding, and kinetics of the 




N heteronuclear single 
quantum coherence (HSQC) experiments are used to show connectivity between nuclei [6]. In 
the repeating nature of a protein’s primary sequence, a series of NH groups from the amino acids 
composing the protein sequence are connected through amide bonds and each becomes 





experiment detects only protons directly coupled to nitrogen [7], and the spectrum displays one 




N chemical shifts for each amide in the protein 
backbone [8].  
 A fingerprint of the protein is created from the HSQC experiment and allows for tracking 
ligand binding, protein behavior, and protein folding [5]. Alterations in the physical or chemical 




N NMR chemical shifts. Protein 
folding imposes unique structural constrains that affect chemical shift positions, distinguishing 





is unfolded, losing its secondary and tertiary structure, the chemical shift distribution for the 
amino acids collapses into a narrow proton ppm range similar to that of small molecule 
compounds which have no preferred orientation and undergo rapid, random motions that average 
on the NMR timescale [9]. When a ligand binds to a protein, the electronic shielding, hence 
magnetic susceptibility, of affected nuclei changes, and perturbations to the backbone amide 
chemical shifts are detected [5, 10]. The protein’s sequential backbone resonance assignments, 
which can be determined through 3D NMR experiments, can be directly tied to the HSQC data, 
allow for determination of the residues involved in ligand binding and provide a basis for 
understanding the inhibition mechanism. In theory, HSQC experiments can be used to track 
amino acid perturbations of MMP-8 from the addition of inhibitors, and correlating the HSQC 
data with the backbone assignments will provide information about where the protein inhibitor 
interaction occurs. Although the crystal structure of MMP-8 was reported previously [11-13], the 
NMR backbone assignments have not yet been determined, and obtaining these assignments 
would help in the determination of the mechanism of MMP-8 inhibition. 
 Inhibitors of enzyme catalytic activity can interact with proteins through various 
mechanisms. The protein inhibitor interactions can be reversible or irreversible and competitive, 
uncompetitive, or non-competitive, and inhibition can be accomplished through direct inhibition, 
allosteric inhibition, direct binding with catalytic ions, or through chelation of the catalytic ions 
[14]. The mechanism of inhibition is unknown for several of the MMP-8 inhibitors that have 
been tested, and understanding the mechanism of protein inhibitor interaction would provide 
useful information for the development of more effective inhibitors. Investigating a mechanism 
of MMP-8 inhibition, recent studies have demonstrated the interaction of MMP-8 with a metal 





degradation by MMP-8 [15, 16]. NCC, a metal abstraction peptide (MAP) with the amino acid 
sequence Asn-Cys-Cys, tightly binds transition metals and has been investigated as a method to 
target metal delivery for treatment and diagnosis of diseases [17]. Although the mechanism of 
interaction has not been confirmed, NCC, when chemically conjugated to 2-aminoethyl 
methacrylate hydrochloride (AEMA) containing dental polymers, is thought to bind to the 
catalytic Zn
2+
 ion in the MMP-8 active site and is a potent inhibitor of the protein enzymatic 
activity [16]. In additional studies using self-assembled monolayers (SAMs), NCC directly 
interacted with MMP-8 through the catalytic Zn
2+
 ion in the active site [15]. NCC has high 
affinity for MMP-8 and is a very slowly reversible inhibitor of enzymatic action. With the 
information from these previous studies, the goal of this project was to determine resonance 
assignments for the protein backbone of MMP-8 using multi-dimensional heteronuclear solution 
NMR and then to use the assignments to study the mechanism of inhibitor interaction to aid in 
the development of more potent and selective MMP-8 inhibitors.   
2.2 METHODS 
2.2.1 Protein Expression and Purification 
 Expression and purification of MMP-8 was completed as previously described using a 
fusion construct with an N-terminal thioredoxin tag (Trx-MMP-8 fusion) [3]. The plasmid for 
Trx-MMP-8 fusion protein was transformed into BL21 Escherichia coli cell strain using the 
standard heat shock method. The cells were incubated overnight at 37 
o
C with 100 μg/mL 






N-labeled cultures, individual colonies were 
inoculated in 50 mL M9ZB media, prepared with ammonium-
15
N chloride, supplemented with 
0.4% glucose, 1 mM MgSO4, and 100 μg/mL ampicillin. The starter cultures were grown for    
16 h at 37 
o
C in an orbital shaker at 250 rpm. Thirty milliliters of the 
15





transferred to 1 L minimal media containing trace minerals and minimal salts [18]. Thirty 




N-labeled cultures was added to inoculate 1 L minimal media containing 








N-labeled media cultures were incubated at 37 
o
C and 250 rpm until the OD600 reached 
approximately 0.7. With the addition of 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG), 
protein expression was induced. After incubating for 4 h at 37 
o
C and 250 rpm, the cells were 
harvested by centrifugation for 8 min at 3,600 x g and 4 
o
C. Cell pellets were stored at -80 
o
C 
until use.  
 To purify MMP-8, each pellet (from 1L of culture) was resuspended in 25 mL lysis 
buffer (50 mM Tris-HCl, 60 mM NaCl, 20 mM imidazole, pH 7.9) and lysed using three passes 
through a French Press at 21,000 psi. Cell lysates were centrifuged at 21,000 x g for 1 h at 4 
o
C, 
and the supernatant, which contained the protein, was filtered through 0.45 μm filter followed by 
a 0.2 μm filters to remove cellular debris. The protein containing sample was applied to a 5 mL 
Hi-Trap Chelating HP column (GE Lifesciences) charged with nickel and equilibrated in lysis 
buffer. To remove cellular proteins, the column was washed with 10 column volumes (CV) of 
wash buffer (50 mM Tris-HCl, 60 mM NaCl, 40 mM imidazole, pH 7.9) at a flow rate of       
1.25 mL/min at 4 
o
C. The protein was eluted from the column using a linear gradient from          
0 to 100% elution buffer (50 mM Tris-HCl, 60 mM NaCl, 500 mM imidazole, pH 7.9). The 
protein containing elution fractions were concentrated using an Amicon Ultra 10 kDa MWCO 
concentrator (Millipore) to approximately 0.6-1.5 mM. The sample was dialyzed in 1 L dialysis 
buffer (50 mM Tris-HCl, 60 mM NaCl, pH 7.9) at room temperature for 1 h in a 10 kDa MWCO 
dialysis cassette followed by 1 h dialysis in fresh 1 L dialysis buffer to remove imidazole. 
Purified samples were stored at 4 
o





2.2.2 SDS-PAGE Analysis 
 SDS-PAGE samples were prepared by mixing 30 μL of sample with an equal volume of 
reducing Laemmli buffer and were heated for 10 min at 90 
o
C before loading onto the gel. Gel 
samples were loaded onto standard 4% (v/v) stacking, 15% (v/v) resolving gels and run at 135 V 
for 2 h and referenced to a prestained, dual-color molecular weight marker (BioRad, #161-0374). 
Gels were stained with Coomassie (R-250) for visualization of protein molecular weight.   
2.2.3 NMR Experiments 
 All NMR experiments were carried out at 25 
o
C using a Bruker Avance 800 MHz NMR 
spectrometer using a cryogenic, triple-resonance probe equipped with pulse field gradients. To 
optimize sample conditions, 0.3 mM 
15
N-labeled MMP-8 protein samples were prepared in       
50 mM Tris-HCl, 60 mM NaCl, pH 8.5, with 5% D2O, unless otherwise noted. Bradford assay 





spectra were collected in 8 scans with 2048 points in the 
1
H dimension and 180 points in the 
15
N 
dimension. HSQC spectra were processed using NMRPipe [19] and analyzed with Sparky [20].  
 For collection of peak assignment data, 3D versions of HNCACB and CBCA(CO)NH 




N HSQC spectra. The HNCACB was 







respectively. The CBCA(CO)NH experiment was collected in 32 scans with 2048, 56, and      










C-labeled MMP-8 protein was incubated with 0.6 mM NCC peptide in 50 mM Tris-HCl, 
60 mM NaCl, pH 8.5 on a laboratory nutator at 20 rpm for 2 h at room temperature. The 
incubation samples were then concentrated to 1.0 mM MMP-8 using Amicon Ultra 30 kDa 










plus bound NCC, 50 mM Tris-HCl, 60 mM NaCl, pH 8.5, with 5% D2O. The 3D NMR data was 
processed using NMRPipe [19] and analyzed in NMR View [21].  
2.3 RESULTS 





N HSQC experiments were performed and the solution conditions of the 





experiments look at the NH bond of the amino acid backbone, Tris is not the most favorable 
buffer because it also has a NH bond, which may produce additional signal in the spectra that 
may interfere with the data. To avoid this complication, lower pH titrations were performed with 
0.3 mM 
15
N MMP-8 in 50 mM sodium phosphate. Overlay of the spectra at various pH (7.9, 7.7, 





N HSQC spectra of MMP-8 pH titration. Sample of 0.3 mM MMP-8 in 50 mM Sodium 
Phosphate at pH 7.9 (red), 7.7 (blue), 7.4 (yellow), and 7.2 (pink) shown (A). The tertiary structure of the protein 
is similar at each pH, but better resolution is observed for some regions of peaks at higher pH (boxed). Zoomed 





more structured, outer peaks from the folded protein decrease in intensity, and the center 
unstructured region is more crowded, which suggests MMP-8 either is unfolding or the 
structured portion is self-associating to form unobservable oligomeric species while the 
unstructured portions of the fusion protein remain visible. As the pH was lowered further to 6.8 
and incrementally reduced to pH 4.0, NMR signal was lost rapidly as MMP-8 precipitated out of 
solution, presumably due to decreased solubility near the protein’s isoelectric point. All the 
protein was recovered in a soluble folded form as the pH was lowered further to pH 3.0. Sodium 
acetate (7.4 mM) was added to the pH 3.0 sample to accomplish buffering. Figure 2.2 shows 
more well-resolved peaks and improved peak resolution in the central region of the spectrum at 






N HSQC spectra comparing MMP-8 at pH 7.9 and pH 3.0. A Sample of 0.3 mM MMP-8 in 50 mM 
Sodium Phosphate, 7.4 mM Sodium Acetate, pH 7.9 (red) and pH 3.0 (purple) shown (A). At pH 3.0, more peaks and 
better resolution are observed throughout the spectra. Fewer peaks and worse resolution are observed in the central 





Titrations at high pH also were carried out in increments of 0.1 pH unit from pH 7.9 to 
8.5 with 0.3 mM 
15
N MMP-8, 50 mM Tris-HCl, 60 mM NaCl. Overlaid spectra of pH titration 
points indicate that resolution of MMP-8 peaks improves with increasing pH (Figure 2.3). 
Unfortunately, chemical exchange of HN protons with the aqueous solvent at basic pH can lead 
to loss of signals in the NMR spectrum. As such, no condition was identified in which the 
expected number of peaks for the entire protein molecule was observed. There are 323 residues 
in the fusion construct, 120, 32, and 152 non-proline residues in Trx, the linker and MMP-8, 
respectively. Under the best condition of 50 mM Tris-HCl, 60 mM NaCl, pH 8.5, 195 peaks 
were observed, which represents 60% of the fusion sequence. This number of peaks is larger 





N HSQC spectra of MMP-8 high pH titration. Sample of 0.3 mM MMP-8 in 50 mM Tris-
HCl, 60 mM NaCl at pH 7.9 (red), 8.0 (blue), 8.1 (yellow), 8.2 (pink), 8.3 (purple), 8.4 (black), 8.5 (green) 
shown (A). The tertiary structure of the protein is similar at each pH, but better resolution is observed for central 
regions of peaks at higher pH (boxed). Zoomed in spectra of pH 7.9 (B) and pH 8.5 (C) show the improved 
resolution at higher pH in the central boxed region. The pH increases may affect the chemical exchange, which 





correspond to MMP-8. The spectra were compared to that of Trx alone to determine if most 
peaks were from Trx or a mixture of MMP-8 and Trx. Clear differences were observed in the 
regions of the spectrum that correspond to unique well-folded portions of the Trx protein. Based 
on the spectral differences, it was anticipated that the peaks reflected at least some structured 
portion of both entities from the fusion construct. 
2.3.2 Effect of metal ions 





 ions. A 0.6 mM 
15
N MMP-8, 50 mM Tris-HCl, 60 mM NaCl, pH 7.9 sample was 
dialyzed in 10 mM Tris base, 7.4 mM sodium acetate, 5 mM CaCl2, 20 μM ZnCl2, pH 7.9. When 
the MMP-8 sample was dialyzed with excess metal ions at pH 7.9, white precipitates formed, 
indicating that the protein precipitated out of solution, but MMP-8 was soluble again when the 




N HSQC, the sample had improved peak 
shape in the presence of the added metal ions compared to the sample at the same pH without 
excess metal ions (Figure 2.4A). The metal ions resulted in peaks with reduced widths at half 
height by approximately 20%, making the peaks sharper and better resolved. 
When further investigated, a MMP-8 sample with excess Ca
2+
 but not excess Zn
2+
 
showed similar structure as compared to the protein without any excess ions (Figure 2.4B). 
Removal of all ions, through dialysis at low pH, resulted in migration of peaks toward the center 
of the HSQC spectra, which indicates loss of protein structure and transition to an unfolded 
protein (Figure 2.4C). The loss of structured protein peaks in the outer regions of the spectrum 
after removing the metal ions suggests the tertiary structure of MMP-8 is dependent on binding 
the zinc ion. The structure of the protein without metal ions was mostly restored after overnight 
incubation with excess Ca
2+
 (5 mM CaCl2) and Zn
2+





affinities of the metal ions to MMP-8 have not been determined, but for comparison, MMP-26 
has one high-affinity and one low-affinity Ca
2+
 binding site with dissociation constants of      
62.9 nM and 120 μM, respectively, at pH 7.5 [22]. It was not determined how much residual zinc 
or calcium was present in the purified protein sample, but both calcium-binding sites should be 





N HSQC spectra of MMP-8 with metal ions. Comparison of sample of 0.6 mM MMP-8 in    
10 mM Tris base, 5 mM CaCl2, 20 μM ZnCl2, pH 3.0 (black) to samples with varying amounts of metal ions. 




 ions (black) improves the MMP-8 structure and resolution of the 
spectral peaks compared to the spectrum when no excess metal ions are added (purple). (B) Excess Ca
2+
 ions 
only (green) do effect the structure slightly through peak shifting, but the Ca
2+
 ions do not affect the structure as 
significantly as when the Zn
2+
 ions are also present. (C) When all the ions are dropped out of MMP-8 (red), the 











MMP on the zinc binding constant. At lower pH, the metal ion affinities will decrease, but the 
addition of excess metal ion will allow for restoration of the ion binding to MMP-8. 
2.3.3 Inhibitor Effects 
 Initial inhibitor studies were investigated using 0.2 mM 
15
N MMP-8 in 50 mM sodium 
phosphate, 7.4 mM sodium acetate, pH 3.0. NNGH, a known inhibitor of MMPs [23], was 
dissolved in DMSO and added to the protein sample in a molar ratio of 19:1 NNGH:MMP-8. 
Several distinct changes were observed in the HSQC of the NNGH-containing sample compared 
to the protein alone. Due to the limited solubility of NNGH in aqueous solution, the resulting 
sample contained 3.4% DMSO. Comparison with a control sample (prepared with the same 
protein sample conditions and amount of DMSO, without NNGH) indicated that the changes 




N HSQC spectra were entirely due to the impact of DMSO on MMP-8 
structure and obscured any more subtle effect of the NNGH interaction with MMP-8, making 
inhibitor specific changes difficult to determine (Figure 2.5). The sample was subsequently 
prepared using 1.0% DMSO, but there was not sufficient improvement in the data to permit 
analysis of the inhibitor binding effect on MMP-8. Further reduction by a meaningful amount in 
the percent solvent was not possible without also substantially decreasing the amount of NNGH 
in the sample. Addition of 3.4% and 1.0% DMSO to the buffer only (10 mM Tris base, 5 mM 
CaCl2, 20 μM ZnCl2, pH 3.0) caused the metal ions to precipitate out of solution. The addition of 
DMSO caused more changes to the protein sample and buffer conditions than the presence of 
NNGH inhibitor, and as such, this line of investigation was terminated.  
Because of the negative impact to protein structure from the addition of DMSO, it 
became evident that water-soluble inhibitors are necessary to study inhibitor interactions with 










N HSQC spectra of MMP-8 with NNGH and DMSO. (A) Sample of 0.2 mM 
15
N MMP-8 in 
50 mM sodium phosphate, 7.4 mM sodium acetate, pH 3.0 (black) compared with samples of same conditions 
and 19:1 NNGH to MMP-8, 3.4% DMSO (blue) shows several spectral perturbations. (B) Comparison of 19:1 
NNGH to MMP-8, 3.4% DMSO (blue) to a control sample with MMP-8 only, 3.4% DMSO (red) shows a 
similar HSQC spectrum. The tertiary structure of MMP-8 is significantly different with the addition of DMSO, 
through the missing and loss of intensity of several peaks. Inhibitor interaction with MMP-8 was not apparent 







inhibitor. NCC has been shown to interact with and bind to MMP-8, and it is proposed to bind 
1:1 to the Zn
2+
 ion in the MMP-8 active site [15, 16]. NCC was slowly titrated into 0.3 mM 
15
N 
MMP-8, 10 mM Tris base, 7.4 mM sodium acetate, 5 mM CaCl2, 20 μM ZnCl2, pH 3.0 in        
0.3 mM NCC increments. Based on previous studies, binding of NCC to MMP-8 qualitatively 
seems to occur on the scale of many minutes to a few hours and is reversible on a longer time 
scale. Because the mechanism of binding has not been elucidated fully and the rate to reach 
equilibrium or saturation has not been determined, the samples were incubated at 4:1 NCC to 




N HSQC data show no detectable differences that would indicate a structural change has 
occurred to MMP-8 when incubated with excess NCC at low pH (Figure 2.6A). This is in 
agreement with previous studies. Studies using Ni
2+
 ions show NCC releases bound metals at 
neutral to low pH [24] and ellipsometry studies using NCC-grafted SAMS show that native, Zn-
bound MMP-8 is released from the surface at pH 3.5 [15]. As such, investigation of NCC 
interaction with NCC was conducted at basic pH. 
 The NMR spectra of MMP-8 were observed to improve upon increasing the sample pH to 
8.5 (section 2.3.1), and higher pH allowed for NCC interaction with MMP-8 (Figure 2.6B). Two 
peaks at approximately 8.8 ppm in the 
1
H dimension and 125 ppm in the 
15
N dimension begin to 
appear and increase in intensity when MMP-8 is incubated with NCC in a 2:1 NCC to MMP-8 
ratio. Peaks at approximately 8.6 ppm in 
1
H and 118 ppm in 
15
N and in the region of 7.8-8.0 ppm 
in the 
1
H dimension and 123-127 ppm in the 
15
N dimension also begin to appear with the 




N HSQC spectrum, the data indicate 
MMP-8 is interacting with NCC and suggest that NCC is binding to the enzyme in a single, 










N HSQC spectra of MMP-8 with NCC. (A) Freshly purified sample of 0.3 mM 
15
N MMP-8 in 
10 mM Tris base, 7.4 mM sodium acetate, 5 mM CaCl2, 20 μM ZnCl2, pH 3.0 (black) did not interact with 4:1 
excess NCC to MMP-8 (red). No spectral perturbations were seen between the two spectra. (B) Freshly purified 
sample of 0.3 mM 
15
N MMP-8 in 50 mM Tris-HCl, 60 mM NaCl, pH 8.5 (black) showed protein interaction 
with 2:1 excess NCC to MMP-8 (red). The presence of new and increased intensity peaks suggests protein-







is possible that more extensive changes are induced upon binding NCC but that the effects are 
not observable using this experimental approach. 
2.3.4 Stability Studies  
 The stability of MMP-8 was analyzed by collecting 2D NMR data at various time points. 
For the stability studies, HSQC experiments were collected on a sample of 0.3 mM 
15
N MMP-8 
in 50 mM Tris-HCl, 60 mM NaCl, pH 8.5, at 16 h, 24 h, 40 h, 64 h, 7.5 d, and 17 d time points.  
MMP-8 stability also was investigated in the presence of NCC. HSQC experiments were 
collected on a sample of 3.0 mM 
15
N MMP-8, 0.6 mM NCC at the same buffer conditions and 




N HSQC spectra show the 
development of new peaks in the region between 7.5-8.2 ppm in the 
1
H dimension and           
124-135 ppm in the 
15
N dimension for both the MMP-8 only sample (Figure 2.7A) and MMP-8 
plus NCC sample (Figure 2.7B). Comparison of the spectra between MMP-8 and MMP-8 with 
NCC inhibition at 17 days shows the presence of new, sharp peaks in the upper region of the 
spectra when NCC is not present (Figure 2.8). These peaks likely represent smaller molecular 
weight fragments and/or disordered portions of the protein that result from proteolytic activity of 
the enzyme. If NCC is inhibiting MMP-8 while it is interacting with the protein, it is possible 
that in the absence of inhibitor, the protein-only sample is experiencing greater autoproteolysis.  
Samples were analyzed using SDS-PAGE to assess the extent of degradation and the 
difference in fragment formation between the samples with longer incubation times. A SDS-
PAGE gel of the samples at the 17 day time point indicates that MMP-8 is still degrading while 
interacting with NCC (Figure 2.9). Immediately following purification (0 days), initial MMP-8 
sample has a molecular weight (MW) of approximately 35 kDa which is consistent with the 










N HSQC spectra of MMP-8 stability with and without NCC. Sample of 0.3 mM MMP-8 in 
50 mM Tris-HCl, 60 mM NaCl, pH 8.5, 0 min (black), 24 h (blue), 64 h (yellow), 7.5 d (purple), and 17 d (red) 
at room temperature shown. (A) With time, MMP-8 only sample develops extra peaks as protein degrades 









NCC (lane 4) at 17 days have faint 
bands at 35 kDa, indicating loss of most 
of the intact MMP-8. However, 
comparison of lanes 3 and 4 shows the 
presence of different bands in each 
lane, and thus unique protein fragments, 
at lower MWs. The two bands around      
12 kDa in lane 3 are shifted to slightly 





N HSQC spectra of MMP-8 stability comparison after 17 days. Sample of 0.3 mM MMP-8 
in 50 mM Tris-HCl, 60 mM NaCl, pH 8.5, 17 days at room temperature shown. MMP-8 only sample (black) and 
the 2:1 NCC to MMP-8 sample (red) develops extra peaks, unique to each sample, as the protein degrades 
(boxed).  
Figure 2.9 Coomassie stained SDS-PAGE gel of MMP-8 
stability samples. (Lane 1) molecular weight ladder, (lane 2)        
0 days post-purification, (lane 3) 17 days post-purification without 
NCC, (lane 4) 17 days post-purification with NCC shown. Post-





has a darker band around 8 kDa. This comparison suggests that the protein degradation pattern 
may be different when NCC is present. The presence of higher MW bands and a more intense 
band around 8 kDa suggests that NCC may be maintaining larger protein fragments, and the 
fragmentation of MMP-8 may be occurring slightly faster in the absence of NCC. Because of the 
high concentration of MMP-8 used in these assays, the fragments generated were attributed to 
autoproteolytic activity, but it should be noted that the samples were generated using a simple 
one-step purification protocol and it cannot be ruled out that contaminating host cell proteins 
may be present that could contribute to proteolytic degradation. 
2.3.5 Temperature Titrations 





N MMP-8, 0.6 mM NCC, 50 mM Tris-HCl, 60 mM NaCl, pH 8.5 (Figure 2.10A). 
Other sample condition optimizations were carried out at 25 
o
C, but small spectral improvements 
with changes in temperature would improve data collected during 3D NMR experiments. 
Lowering the NMR temperature to 20 
o
C resulted in decreased resolution in the center of the 
spectra (Figure 2.10B). An increase in the temperature to 30 
o
C yielded better resolution, and the 






N HSQC experiments             
(Figure 2.10C).  
2.3.6 3D NMR Experiments  
 To determine the NMR assignment data for MMP-8, the 3D CBCA(CO)NH and 




C MMP-8 plus bound NCC, 50 mM 
Tris-HCl, 60 mM NaCl, pH 8.5. The sample used for the 3D experiments was at pH 8.5 to allow 
for MMP-8 interaction with NCC. At an enzyme concentration of 1.0 mM and above, self-





toward the center of the spectrum. Dilution of the sample was slow to reverse the MMP-8 self-
association. Concentrating the sample after incubation of a 0.3 mM MMP-8 sample with 0.6 mM 
NCC prevented protein aggregation, so the 3D experiments were collected on samples 




N axes should display 




N chemical shifts as the HSQC spectrum (Figure 2.11). In the 
CBCA(CO)NH, the peaks are concentrated in the center, and most of the outer, structured peaks 
are missing (Figure 2.12). For each amino acid, the strip plot of the CBCA(CO)NH 3D data 
should display the two peaks that correspond to the Cα and Cβ of the preceding amino acid 





N HSQC spectra of MMP-8 temperature. Sample of 0.3 mM MMP-8, 0.6 mM NCC in 50 
mM Tris-HCl, 60 mM NaCl, pH 8.5, 20 
o
C (black), 25 
o
C (red), 30 
o
C (blue), and 35 
o
C (yellow) shown. With 
increasing temperature, the resolution improves in the central region of the spectra (boxed). Zoomed in spectra 
of 20 
o
C (B) and 35 
o






resonances are not detected in the experiment or the strips have more than two peaks and are 
difficult to interpret due to overlap of the data.  




N plane also shows missing 
peaks and peaks with reduced intensity in the outer, structured regions of the spectra (Figure 
2.14). For this experiment, each HN should have four associated peaks that correspond to the Cα 
and Cβ of the same amino acid and of the preceding residue. This is represented in the strip plot 
for each amino acid. Only 25% of the peaks in the HSQC have four peaks in their strip plots, and 
connectivity to either the preceding or following amino acid in the protein sequence could not be 
made for many of those peaks (Figure 2.15). Another challenge with this data set is the absence 





N HSQC spectra of MMP-8 for peak assignments. Sample of 1.0 mM MMP-8 plus NCC in  













N plane of 3D data from the CBCA(CO)NH 
experiment for a sample of 1.0 mM MMP-8 + NCC in 50 mM Tris-HCl, 60 mM NaCl, pH 8.5 shown. The 




N HSQC spectra, indicate where missing peaks in this data set should 
be located in the CBCA(CO)NH spectrum.  
 
Figure 2.13 Example strip plot of CBCA(CO)NH data from MMP-8. Sample of 1.0 mM MMP-8 + NCC in 
50 mM Tris-HCl, 60 mM NaCl, pH 8.5, CBCA(CO)NH strips with good data, showing 1 Cα and 1 Cβ peak, 












N plane of 3D data from HNCACB experiment for a 
sample of 1.0 mM MMP-8 + NCC in 50 mM Tris-HCl, 60 mM NaCl, pH 8.5 shown. The numbers, which are 




N HSQC spectra, indicate where peaks should be located in the HNCACB spectrum.  
 
Figure 2.15 Example strip plot of HNCACB data from MMP-8. Sample of 1.0 mM MMP-8 + NCC in        
50 mM Tris-HCl, 60 mM NaCl, pH 8.5, HNCACB strips with good data, showing 2 Cα and 2 Cβ peaks, (green), 






3D data set. Without having all four peaks, it is impossible to derive connectivity between the 
amino acids in the polypeptide chain. The data from the HNCACB experiment was even less 
complete, and resonances for only 15% of the Trx MMP-8 fusion amino acid residues were 
present in the spectrum. Because these experiments produced only a very small fraction of the 
peaks observed in the best 2D HSQC, and this represented only 60% of the protein at most, it 
was concluded that even partial NMR assignments of MMP-8 could not be made under the 
conditions chosen based on the 2D range-finding HSQC experiments.  
2.4 DISCUSSION 
 Condition optimization experiments for MMP-8 provide interesting information about the 
protein’s behavior in different chemical environments, its stability, and protein-inhibitor 
interactions. The structure of MMP-8 was improved at lower pH, as observed with better peak 













N HSQC compared to samples at 
higher pH. The metal ions do not bind covalently to MMP-8 and follow the principle of 
equilibrium. When MMP-8 is purified, metal ions occupy the metal binding sites, but during 
purification, excess ions are removed to some extent. With time, the equilibrium of bound vs free 
ions shifts since few to no ions occupy the surrounding environment initially. At low pH, the 
binding affinity of the metals is lower due to competition for binding with increased protons in 
the sample solution. Without the addition of excess metal ions, exchange occurs and the average 





ions are added, the protein obtains a more rigid and less flexible structure since the equilibrium 









 ions in MMPs are important for structure and enzymatic function [25]. 
However, little research has focused on the mechanisms of the structural and functional roles of 
the metal ions in MMP-8. Functional MMP-8 coordinates one catalytic Zn
2+
 ion, an additional 
structural Zn
2+
 ion, and two structural Ca
2+
 ions [11]. By using NMR alone, it is difficult to say 
which ion(s) were lost through dialysis of MMP-8 at low pH and which are important for 
maintaining tertiary structure. From the low pH dialysis studies, it was determined that Zn
2+
 ions 
are lost during purification to an appreciable extent and that zinc is more important for enzyme 
structure compared to the Ca
2+
 ions. From the current data set, it cannot be determined whether 
one or both of the Zn
2+





 ions and the mechanism of the ions’ functions, enzymatic action and/or structural 
roles, are currently not established.  
In a study with MMP-26, which also has two Ca
2+
 ions, sequence alignment with other 
MMPs and crystal structure analysis indicated the presence of both a low and a high affinity Ca
2+
 
ion. The low affinity Ca
2+
 ion (120 μM dissociation constant) was more easily dialyzed out of 
the protein, caused structural changes at the catalytic site, which is important for regulation of 
enzymatic activity, and resulted in a decrease of catalytic activity (Figure 2.16) [22]. 
Additionally, the removal of the high-affinity Ca
2+
 ion (62.9 nM dissociation constant), which is 
important for protein folding and initial stabilization of the tertiary structure, did not affect the 
tertiary protein structure.  
The mechanisms and functions of the metal ions do vary between the MMPs, so it is not 
possible to predict accurately the role of the metal ions in MMP-8 from the study with MMP-26. 
Most of the residues that do coordinate the metal ions, described below, are conserved in all 





MMP-8 [12]. Comparison of MMP-8 and MMP-
26 structures indicate similarities, so the Ca
2+
 
ions may have similar roles in MMP-8. Based on 
the binding constant, by analogy the low-affinity 
site would be empty but the high-affinity site 
would likely remain occupied with calcium 
following purification of MMP-8 in this study. 
Future studies of MMP-8 using a series of 
mutants to investigate the effects of metal 
chelators, including activity assays and structural 
analyses such as circular dichroism (CD) 
spectroscopy, may contribute more information 
about which metal ions are important for structure 
and function and their affinities to MMP-8.  
 Without knowing which ions are removed 
in dialysis and if they impact the tertiary 
structure, it is possible that the removal of the 
catalytic Zn
2+
 ion resulted in loss of tetrahedral ligation, and thus the loss of structure was 




N HSQC spectra. The catalytic Zn
2+
 ion of MMP-8 is liganded by the 
imidazole nitrogen atoms from three histidine residues (Figure 1.3) [26]. The other Zn
2+
 ion, 
thought to maintain tertiary structure, is also tetrahedrally coordinated by three histidine residues 
and an aspartic acid residue [12]. One of the Ca
2+
 ions has octahedral coordination involving two 
aspartic acid residues, one glutamic acid residue, one glycine residue, and the backbone of one 
Figure 2.16 MMP-26 structure comparison. 
The light gray ribbon shows MMP-26 structure in 
the presence of low affinity Ca
2+
 ions, and the 
dark gray ribbon shows the structural changes 
when these ions are removed. The light gray 
spheres, C2 and C3, indicate possible low affinity 
Ca
2+
 ions, where C2 most likely is not a Ca
2+
 ion 
binding location. The dark gray sphere, C1, 
indicate the high-affinity Ca
2+
 ion. The small light 
and dark gray spheres represent the Zn ions in the 
presence and absence of low affinity Ca
2+
 ions, 
respectively. Reproduced with permission from, 






isoleucine residue. The other Ca
2+
 ion is coordinated between two glycine residues and two 
aspartic acid residues, as determined in the 2OY4 uninhibited MMP-8 crystal structure in the 
Protein Data Bank [27]. At low pH, the nitrogen of the histidine residues and the oxygen atoms 
of the glutamic acid and aspartic acid residues become protonated, and the protons reduce the 




 ions for the protein 
binding sites. With low pH dialysis, the metal ions ultimately are removed from their 
coordination sites and replaced with hydrogen atoms, which removes the structural interaction 
between distal amino acids and results in loss of tertiary structure. The Ca
2+
 ion described above 
is within a compact loop structure that is thought to stabilize the whole domain, so loss of this 
ion would result in unfolding of MMP-8 [12]. As such, the HSQC spectra of the purified MMP-8 
sample and MMP-8 with excess calcium added indicate that this Ca
2+
 ion largely remains bound 
during purification of the enzyme. The addition of excess metal ions helped to saturate the 
binding sites and stabilize the protein structure by driving the equilibrium of the metals to the 
liganded state, thereby improving the NMR spectrum by reducing conformational exchange.  
Further investigations of MMP-8 at low pH were studied with the addition of inhibitors. 
Interactions between NNGH and MMP-8 were unable to be determined because DMSO, the 
solvent for NNGH, greatly changed the structure of MMP-8. DMSO denatures a protein, 
disrupting secondary structure, by breaking hydrogen bonds, hydrophobic interactions, and salt 
bridges [28]. Because of this, the water-soluble inhibitor NCC was used in an effort to study the 
mechanism of inhibition of MMP-8. Testing of the NCC peptide by previous group members has 
indicated that NCC will coordinate Zn
2+
 ions. When NCC was previously incubated with and 
bound to a metal, it did not interact with MMP-8, which further suggests that NCC interacts with 
the Zn
2+





with MMP-8 [15, 16]. However, as expected from studies involving other divalent cations, NCC 
did not interact with MMP-8 at low pH. Previous studies demonstrate that NCC releases Ni
2+
 
ions at neutral pH. The exact pH profile for NCC binding to Zn
2+
 ions has not been determined 
experimentally, but it is known that pH 3.0 is a low enough pH for NCC to not bind and to 
release bound Zn
2+
 ions.  
Because NCC did not interact with MMP-8 at low pH, the sample was studied further at 
basic pH. Each of the amino acids composing a protein has a distinct charge state and the protein 
has an isoelectric point derived from its unique composition. Adjusting the sample pH can cause 
protonation or deprotonation of the ionizable side chain moieties, including carboxylic acids, 
amines, imidazoles, and thiols. Altering the pH of the solution affects the solubility of the 
protein, decreasing it as the solution approaches the protein’s isoelectric point. Changes in pH 
also can lead to localized or global transitions in protein structure or confirmation [29, 30] and 
stability of the fold as well. Protonation or deprotonation of a residue causes changes in the 
electric field surrounding the nuclei involved and neighboring residues [31, 32], which are 
detectable in the NMR as chemical shift perturbations [33].  All of these possible changes in the 
chemical environment as an effect of pH, protein folding and ligand interactions, can lead to 
chemical shift changes in the HSQC spectrum for most nuclei in a protein and may impact 
spectral resolution. 
In investigations at basic pH (8.5), chemical shift changes in the presence of NCC were 
observed and therefore the site of interaction with MMP-8 could be characterized using this 




N HSQC spectrum suggest that the interaction is in 
one localized area of MMP-8 and most of the protein structure remains unchanged. Due to the 
metal binding properties of NCC, the peptide is expected to interact directly with the Zn
2+





the MMP-8 active site. Based on the NMR data, it must be concluded that the peptide does so 
without displacing other coordinating ligands or more likely that this critical portion of the 
enzyme simply is absent from the spectra, preventing the use of perturbation analysis to detect 
the binding site. What is clear from the present data set, and confirms previous conclusions, is 
that NCC does not remove metal ions from MMP-8 [15]. It is known that NCC does not bind 
Ca
2+
, so any observed changes would be attributable to its interaction with Zn
2+
. It was 
established in Tucker et al. that NCC binds the Zn
2+
 ion while it remains coordinated by MMP-8 
[15]. If the Zn
2+
 ion was removed from the protein during the long incubation period, the tertiary 
structure would change significantly, and the HSQC spectrum would appear similar to the 
spectrum in which the metal ions were removed from the protein by dialysis at low pH. 
Unfortunately our data set was insufficient to characterize the interaction, and more complete 3D 
data to support peak assignment is needed to confirm how NCC interacts with the Zn
2+
 ion in the 
MMP-8 active site.  
 The stability of the MMP-8 protein sample also was a concern because the 3D NMR 
experiments require the sample to be at or above room temperature for several days. The 
proteolytic function of MMPs allows for increased autoproteolysis at these temperatures, which 
makes production of stable proteins difficult [2]. The structure of MMP-8 remains mostly intact 
upwards of 7 days, which means the sample will be stable enough for the collection of the 3D 
NMR experiments. However, several new peaks around 7.5-8.2 ppm in the 
1
H dimension and 
124-135 ppm in the 
15
N dimension in the spectra, both with and without NCC inhibition, develop 
within a couple days. The presence of new peaks suggests that while the protein chain remains 
largely intact during this period, MMP-8 structure is deteriorating with time, even within the 4 to 









N HSQC of 
the samples at 17 days shows the presence of several new peaks around 8.3-9.0 ppm in the       
1
H dimension and 105-110 ppm in the 
15
N dimension when NCC is not present. It is possible that 
NCC is preventing some degradation and change in the MMP-8 protein structure that normally 
occurs without inhibition. Previous studies have shown that in the presence of NCC, MMP-8 
activity is reduced, and in the absence of NCC, enzyme activity is retained even after 
fragmentation [3]. With the structural changes and degradation, it is also possible that NCC is 
changing the cleavage pathway.  
After 17 days at room temperature, the protein sample is significantly degraded from its 
original band on the SDS-PAGE gel, even in the presence of NCC. From visual analysis of the 
gel, both samples no longer have the intact protein after 17 days. The remaining bands on the gel 
are different between the sample with and without NCC, which indicates a differences in 
fragmentation rate or pattern. SDS-PAGE gels were not run at other time points, so it is difficult 
to draw conclusions about MMP-8 degradation. Further SDS-PAGE stability studies at 
additional time points will need to be completed to better understand the rate of MMP-8 
degradation and effectiveness of NCC inhibition.  
With other metals, NCC has been demonstrated to abstract the metal ion, removing it 
from the original chelating group and sequestering it in basic solutions. It is possible that the 
same reaction occurs with zinc but at a greatly reduced rate. If this is happening slowly in the 
NCC-containing MMP-8 sample, then unfolding of the enzyme should occur.  
The peaks that appear in the HSQC of the NCC-containing sample over time correspond 
to the chemical shift region where sequences lacking stable structure appear. The appearance of 





that hallmarks of degradation appear in both MMP-8 spectra but differ in the absence and 
presence of NCC suggest that ultimately the metal ion may be abstracted by the inhibitor. This 
hypothesis is consistent with all existing data but further investigation would be required to 
explore this possible mechanism. 
 Several factors explain reasons for the unsuccessful 3D NMR experiments. The Trx-
MMP-8 fusion protein consists of 323 amino acids, which is large for standard 3D NMR studies. 
Nonetheless, many proteins of this size or larger have been studied successfully using high-
resolution solution NMR [34-36]. MMP-8, Trx, and the S-Tag make up 161, 126, and 33 amino 







C chemical shifts for amino acids based on their chemical environment, so larger proteins 
may yield overlapping peaks, as more peaks need to fit within the same chemical shift range 
[37]. Poor resolution in NMR experiments of proteins may also result from non-ideal relaxation 




N HSQC had good resolution and intensity of peaks, the 
sensitivity of the experiment and therefore the intensity of peaks inherently decrease with 3D 
NMR experiments. For 3D data collection, more time is needed for data acquisition, and longer 
pulse sequences are required [37]. For a 30 min 2D HSQC, 180 points were collected for the   
15





C dimensions, respectively. With fewer data points for 3D experiments, the signal 
intensity and resolution will decrease. To help overcome reduced signal intensity, higher MMP-8 
concentration samples were used.  
 Several paths forward are possible to attempt to improve the 3D NMR data quality and 
allow for protein assignment. Using a deuterated protein would allow for shorter relaxation 





Trx-MMP-8 protein would need to be grown up in E. coli in 100% D2O with deuterated           




C. This labeling technique is expensive and with the very 
large number of peaks missing from the 3D data set that appear in the 2D data, this approach is 
not likely to yield a greatly improved outcome. The HN chemical exchange is likely the biggest 
problem at basic pH, so using a deuterated protein may not offer the best solution. It is likely that 
chemical exchange at basic pH and the intermediate time scale of protein dynamics and 
conformational changes result in data loss. Improvement in solubility of the fusion protein near 
neutral pH could be altered to allow for collection of data at conditions that allow for better 
chemical exchange. Another option to test before trying deuteration would be to further 




 ions, the 
HSQC of MMP-8 fusion displayed sharper, better resolved peaks. Conducting the 3D NMR 
experiments at a low pH and with excess metal ions may result in better 3D data for a greater 
percentage of the protein sequence. This approach would not, however, provide information 
about how NCC interacts with MMP-8 because NCC does not interact with the enzyme at low 
pH, and the excess ions may interfere with NCC binding to the enzyme if it coordinates excess 
Zn
2+
 ions. If the conditions with low pH and excess ions do allow for improved signals in the 3D 
NMR experiments, this condition may be useful to investigate MMP-8 interactions with other 
inhibitors. 
 Because the main goal of the study was to understand the mechanism of inhibitor 
interaction with MMP-8, selective labeling of amino acids that are present in and around the 
MMP-8 active site might allow for identification of the inhibitor binding location. From previous 
crystal structure data, the active site pocket does consist of a leucine residue, so ILV labeling 





perturbations at the active site from inhibitor interactions [38]. In the active site, 3 histidine 
residues interact with the Zn
2+
 ion, so selective 
15
N-labeling of Trx-MMP-8 histidine residues 
would also indicate changes at the active site if inhibitors are interacting with Zn
2+
 [39]. If     
ILV labeling and selective 
15
N-labeling techniques were investigated, several mutations in the 




N HSQC spectra correspond to the leucine or histidine residues in the MMP-8 active site, 
and making multiple mutations takes additional time and resources. This approach would require 
that the inhibitors interact at a site on MMP-8 where ILV methyl labels are present. Even with all 
these possible future paths, improved and successful data that allows for spectral assignment 
and/or determination of inhibitor interaction is not a guarantee.  
2.5 CONCLUSIONS 
 In these studies, the structural role of the metal ions of MMP-8 was observed, and a range 
of sample conditions were investigated to identify a path to 3D NMR data collection to 
accomplish backbone resonance assignment. Trx-MMP-8 has been shown to interact with the 
metal binding peptide NCC. Although the backbone assignments were not able to be determined, 
further insight into the protein-inhibitor interaction was established. From the NMR studies, 
NCC does interact with MMP-8 in a localized region, most likely interacting with the Zn
2+
 ion in 
the active site. To further understand the mechanism of inhibitor interaction, alternate protein 
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